Pivotal is pleased to announce that it has received French research tax credit approval for years 2013 through 2015.
According to Lidia Farr Corporate Development at Pivotal "We are extremely pleased to receive this approval from the French Ministry of Research since it will provide Pivotal with greater opportunities to support current and future customers in this important European market".
The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche", CIR) accreditation to Pivotal as of July 2013.
"This initiative allows eligible research-intensive French companies who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D requirements that are outsourced to Pivotal" declared Dr. Lourdes Huarte, VP, Clinical and Regulatory at Pivotal.
About Pivotal S.L.
Pivotal is a leading privately held Spanish based Contract Research Organization (CRO) with a solid presence across Western Europe (directly, via partners or known contractors). The Company has 12 years of experience and an unrivalled track record of delivering all ranges of clinical research services to multinational and local Pharmaceutical and Biotechnological companies. Pivotal has successfully grown its business organically since it was founded in November 2001 developing clinical trials in all therapeutic areas with a special emphasis on Oncology, Cell Therapy, Cardiovascular, Diabetes, Central Nervous System, Immune-based, Infectious and other disease areas.
Please visit www.pivotal.es for more information.
For further contact: Natalia Farr (email@example.com); Communication Department, Pivotal S.L. +3491 7081250